Science
Unpredicted binding found between SARS-CoV-2 and hepatitis C drug, telaprevir – Drug Target Review
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Scientists have found new, unexpected behaviours when SARS-CoV-2 – the virus that causes COVID-19 – encounters drug inhibitors, which bind to certain components of the virus and block its ability to reproduce.
According to the team, from the US Department of Energy’s Oak Ridge National…
-
General12 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General12 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News21 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General12 hours agoOf saints and sinners | The Spectator Australia